Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine

Minjee Kim, Sani Kizilbash, Janice K. Laramy, Gautham Gampa, Karen E. Parrish, Jann N Sarkaria, William F. Elmquist

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The treatment of metastatic lesions in the brain represents a serious unmet medical need in the field of neuro-oncology. Even though many effective compounds have demonstrated success in treating peripheral (non-CNS) tumors with targeted agents, one aspect of this lack of success in the brain may be related to poor delivery of otherwise effective compounds. Many factors can influence the brain delivery of these agents, but one key barrier is a heterogeneously “leaky” BBB that expresses efflux transporters that limit the BBB permeability for many targeted agents. Future success in therapeutics for brain metastases must take into account the adequate delivery of “active, free drug” to the target, and may include combinations of targeted drugs that are appropriate to address each individual patient’s tumor type. This review discusses some issues that are pertinent to precision medicine for brain metastases, using specific examples of tumor types that have a high incidence of brain metastases.

Original languageEnglish (US)
Article number177
JournalPharmaceutical Research
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Drug therapy
Precision Medicine
Medicine
Brain
Neoplasm Metastasis
Pharmaceutical Preparations
Tumors
Therapeutics
Neoplasms
Oncology
Drug Combinations
Permeability
Incidence

Keywords

  • blood-brain barrier
  • brain metastases
  • drug delivery
  • efflux transporters
  • metastasize
  • molecularly-targeted anti-cancer agents

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Barriers to Effective Drug Treatment for Brain Metastases : A Multifactorial Problem in the Delivery of Precision Medicine. / Kim, Minjee; Kizilbash, Sani; Laramy, Janice K.; Gampa, Gautham; Parrish, Karen E.; Sarkaria, Jann N; Elmquist, William F.

In: Pharmaceutical Research, Vol. 35, No. 9, 177, 01.09.2018.

Research output: Contribution to journalReview article

Kim, Minjee ; Kizilbash, Sani ; Laramy, Janice K. ; Gampa, Gautham ; Parrish, Karen E. ; Sarkaria, Jann N ; Elmquist, William F. / Barriers to Effective Drug Treatment for Brain Metastases : A Multifactorial Problem in the Delivery of Precision Medicine. In: Pharmaceutical Research. 2018 ; Vol. 35, No. 9.
@article{2f472e7ef54848e283a909c2a884cfc1,
title = "Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine",
abstract = "The treatment of metastatic lesions in the brain represents a serious unmet medical need in the field of neuro-oncology. Even though many effective compounds have demonstrated success in treating peripheral (non-CNS) tumors with targeted agents, one aspect of this lack of success in the brain may be related to poor delivery of otherwise effective compounds. Many factors can influence the brain delivery of these agents, but one key barrier is a heterogeneously “leaky” BBB that expresses efflux transporters that limit the BBB permeability for many targeted agents. Future success in therapeutics for brain metastases must take into account the adequate delivery of “active, free drug” to the target, and may include combinations of targeted drugs that are appropriate to address each individual patient’s tumor type. This review discusses some issues that are pertinent to precision medicine for brain metastases, using specific examples of tumor types that have a high incidence of brain metastases.",
keywords = "blood-brain barrier, brain metastases, drug delivery, efflux transporters, metastasize, molecularly-targeted anti-cancer agents",
author = "Minjee Kim and Sani Kizilbash and Laramy, {Janice K.} and Gautham Gampa and Parrish, {Karen E.} and Sarkaria, {Jann N} and Elmquist, {William F.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s11095-018-2455-9",
language = "English (US)",
volume = "35",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Barriers to Effective Drug Treatment for Brain Metastases

T2 - A Multifactorial Problem in the Delivery of Precision Medicine

AU - Kim, Minjee

AU - Kizilbash, Sani

AU - Laramy, Janice K.

AU - Gampa, Gautham

AU - Parrish, Karen E.

AU - Sarkaria, Jann N

AU - Elmquist, William F.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The treatment of metastatic lesions in the brain represents a serious unmet medical need in the field of neuro-oncology. Even though many effective compounds have demonstrated success in treating peripheral (non-CNS) tumors with targeted agents, one aspect of this lack of success in the brain may be related to poor delivery of otherwise effective compounds. Many factors can influence the brain delivery of these agents, but one key barrier is a heterogeneously “leaky” BBB that expresses efflux transporters that limit the BBB permeability for many targeted agents. Future success in therapeutics for brain metastases must take into account the adequate delivery of “active, free drug” to the target, and may include combinations of targeted drugs that are appropriate to address each individual patient’s tumor type. This review discusses some issues that are pertinent to precision medicine for brain metastases, using specific examples of tumor types that have a high incidence of brain metastases.

AB - The treatment of metastatic lesions in the brain represents a serious unmet medical need in the field of neuro-oncology. Even though many effective compounds have demonstrated success in treating peripheral (non-CNS) tumors with targeted agents, one aspect of this lack of success in the brain may be related to poor delivery of otherwise effective compounds. Many factors can influence the brain delivery of these agents, but one key barrier is a heterogeneously “leaky” BBB that expresses efflux transporters that limit the BBB permeability for many targeted agents. Future success in therapeutics for brain metastases must take into account the adequate delivery of “active, free drug” to the target, and may include combinations of targeted drugs that are appropriate to address each individual patient’s tumor type. This review discusses some issues that are pertinent to precision medicine for brain metastases, using specific examples of tumor types that have a high incidence of brain metastases.

KW - blood-brain barrier

KW - brain metastases

KW - drug delivery

KW - efflux transporters

KW - metastasize

KW - molecularly-targeted anti-cancer agents

UR - http://www.scopus.com/inward/record.url?scp=85049944792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049944792&partnerID=8YFLogxK

U2 - 10.1007/s11095-018-2455-9

DO - 10.1007/s11095-018-2455-9

M3 - Review article

C2 - 30003344

AN - SCOPUS:85049944792

VL - 35

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 9

M1 - 177

ER -